About SemBioSys Genetics Inc. (http://www.sembiosys.com)
Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and animal health markets. More information is available and can be accessed at http://www.sembiosys.com.
About Croda International Plc
Croda International is a UK-based manufacturer of speciality
ingredients derived mainly from naturally occurring and renewable raw
materials. The market-driven company is renowned for its scientific and
technological focus, supplying innovative and sustainable ingredients to
global consumer care and industrial specialities markets. Its broad product
range includes skin, hair and sun care actives, proteins and derivatives,
high purity lipid concentrates, lanolins, and polymeric surfactants used in
many personal care, home care, health care and crop care applications.
Globally Croda International Plc had sales of pnds stlg 886.1m (USD1.76b)
in 2007, and recorded a pre-tax trading pr
|SOURCE SemBioSys Genetics Inc.|
Copyright©2008 PR Newswire.
All rights reserved